This web site uses cookies. Do you accept the use of external cookies? Yes No Know more x
Survey about achondroplasia
We have designed a questionnaire with the purpose to better know the population connected to achondroplasia.
The questionnaire is optional and anonymous. The data obtained will be used for statistical purposes and to better understand the natural history of achondroplasia. Please consider answering.
If you would like to take the survey later, you can click on the link at the top "Register at BA"

Pfizer acquired Therachon. And now what to expect?

2019-05-14Global
Pfizer announced on the 9th May 2019 that it has entered into a definitive agreement to acquire all the shares of Therachon Holding AG, a clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia and short bowel syndrome (SBS).

Highlights on the 6th International ALPE Congress on Achondroplasia & Other Dysplasias

2018-10-23Global
One of most relevant events on achondroplasia was held by ALPE Foundation (based in Spain), on the 12,13 and 14th October 2018, bringing together leading healthcare experts in dysplasias, pharmaceutical companies, patient organizations, and more than 500 participants.

This is the new Beyond Achondroplasia - a multilingual platform

2018-06-23Global
Beyond Achondroplasia is now converted into a multilanguage platform, with a new image and structure. We are launching it in English, Spanish, Portuguese and Russian. It will now be easier to find the information you need about achondroplasia.

European Patient Advocacy Groups (ePAG) Registration Form for Patient Organisations

2016-11-24Global
EURORDIS is calling for patient organizations to join the European Patient Advocacy Groups. Learn more about them and how to apply here.

Funding opportunities for projects dedicated to children with rare diseases

2016-04-12Global
There are several funds and foundations that fund projects for children with rare diseases. Here is a list of some of them, as well as what their aims are and their deadlines.
To view this site you need Internet Explorer 8 (or a higher version)
or another internet browser.


Thank You.